Second Quarter 2018

cryoport

SCIENCE. LOGISTICS. CERTAINTY.

Trusted by the Life Sciences Industry

cryoport

SCIENCE. LOGISTICS. CERTAINTY.

Safe Harbor – Forward Looking Statements

This presentation contains certain forward-looking statements that involve risks and uncertainties. Such forward-looking statements include statements regarding attempts to identify new strategic opportunities which may include a strategic transaction, plans regarding partnering activities, product pricing, financial forecasts. Such statements are only predictions and the Company's actual results may differ materially from those anticipated in these forward-looking statements. Factors that may cause such differences include the risk that the Company may not be able to identify acceptable strategic opportunities or conclude any strategic transaction which it does identify, the risk that products that appeared promising in early use do not demonstrate the same utility in larger-scale uses, the risks associated with the Company's reliance on outside financing to meet its capital requirements, and the risks associated with the Company's reliance on collaborative partners for shipping. Forward-looking statements are inherently subject to risks and uncertainties, some of which cannot be predicted, or quantified. Future events and actual results could differ materially from those set forth in, contemplated by, or underlying the forward-looking statements. The risks and uncertainties to which forward-looking statements are subject include, but are not limited to, the effect of government regulation, competition and other material risks. These factors and others are more fully discussed in the Company's periodic reports and other filings with the Securities and Exchange Commission.

Quarterly Overview

Business description	**Leading temperature-controlled logistics solutions provider for the life sciences industry with a focus on the regenerative medicine market (e.g., CAR-T)**
Clients	**Pharmaceutical and biotechnology companies (e.g., Novartis, Gilead/Kite[(a)], Atara, Zoetis etc.)**
Markets	**Biopharma, Reproductive Medicine, and Animal Health**
Commercial Biopharma Agreements	**Novartis and Gilead/Kite**
Number of Clinical Trials Currently Supported	**258, 34 of which are in Phase III**
Revenue Growth Year-over-Year	**59%**
Q1 2018 Gross Margin	**54%**
Biopharma Revenue Growth Year-over-Year	**73%**
CEO	**Jerrell Shelton**
Headquarters	**Irvine, CA**

(a) Kite was acquired by Gilead Sciences in October 2017

Global Logistics Centers & Volume Heat Maps

- **866 Global Regenerative Medicine Companies (up from 672 in 2016) – 466 North America, 235 Europe and Israel, 127 Asia, and 16 RoW.**
- **May, 2018 Gilead announced a new Yescarta™ manufacturing facility would be built in Amsterdam, Netherlands.**
- **July, 2018 Novartis announced Kymriah™ manufacturing centers in Paris, France and Leipzig, Germany.**
- **New Cryoport Global Logistics Centers in Livingston, New Jersey and Amsterdam, Netherlands.**





Global Transportation Partnerships

Cryoport's solutions have global reach through shipping agreements with FedEx, UPS, DHL, and World Courier

FedEx

FedEx® Deep Frozen Shipping Solution

powered by Cryoport®



DHL THERMONET

cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Clinical Trials Drive Revenue Growth in Biopharma

22 new clinical trials (net) added in Q2-2018; 86 clinical trials (net) added since Q2-2017; 34 Phase III



Primary Target Market: Regenerative Therapy

977

Clinical trials underway[a]

804 year-end 2016[b]
631 year-end 2015[b]

Ph. I: 324

(261 in 2016)
(192 in 2015)

Ph. II: 560

(475 in 2016)

(376 in 2015)

Ph. III: 93

(68 in 2016)
(63 in 2015)

- **Industry inflection point: Commercialization has begun**
- **Novartis' CAR-T drug, Kymriah™, approved in August 2017 and Gilead/Kite therapy, Yescarta™, approved in October 2017**
- **Kymriah™ second indication approved on 5/1/18**
- **Two EMA's filed and one EMA approved so far in 2018**
- **At least 4 additional BLA/EMAs for regenerative therapies expected to be filed in 2018**
- **532 of all current clinical trials are in oncology**
- **Total of 20 Regenerative Medicine Advanced Therapy designations granted**

(a) Alliance for Regenerative Medicine, July 1, 2018
(b) Alliance for Regenerative Medicine, March 7, 2017

Chain of Compliance™ Logistics Management

CHAIN of CUSTODY **CHAIN of CONDITION** **CHAIN of IDENTITY** **CHAIN of COMPLIANCE™**



Traceability of the Custody of each Client's or Patient's Therapy	Traceability of the Condition of each Client's or Patient's Therapy	Traceability of the Identity of each Client's or Patient's Therapy	Traceability of the Equipment and Processes Supporting each Client's or Patient's Therapy

Supports regulatory compliance requests from the EMA/FDA and other regulatory agencies

EUROPEAN MEDICINES AGENCY
SCIENCE MEDICINES HEALTH

FDA U.S. FOOD & DRUG ADMINISTRATION

Current FDA Approved RMAT Designations

Company	Product	Indication	Website	Year
Asterias Biotherapeutics	AST-OPC1	Spinal Cord	www.asteriasbiotherapeutics.com	2017
Athersys	Multistem	Ischemic Stroke	www.athersys.com	2017
Bluebird Bio	Lentiglobin	Sickle Cell	www.bluebirdbio.com	2017
Cellvation	CEVA101	Brain Injury	www.cellvation.com	2017
Humacyte	Humacyl	Hemodialysis	www.humacyte.com	2017
Enzyvant	RVT-802	DiGeorge Syndrome	www.enzyvant.com	2017
Jcyte	jcell	Retinitis Pigmentosa	www.jcyte.com	2017
Juno Therapeutics	JCAR017	Lymphoma	www.junotherapeutics.com	2017
Kiadis Pharma	ATIR101	Leukemia	www.kiadis.com	2017
Mallinckrodt Pharma	Stratagraft	Thermal Burns	www.mallinckrodt.com	2017
Mesoblast	MPC-150-IM	Heart Failure	www.mesoblast.com	2017
Vericel Corp.	lxymelocel-T	Dialated Cardiomyopathy	www.vcel.com	2017
Abeona Therapeutics	EB-101	Recessive RDEB	www.abeonatherapeutics.com	2018
Abeona Therapeutics	ABO-102	Sanfilippo Syndrome	www.abeonatherapeutics.com	2018
Caladrius Biosciences	CLBS14	Refractory Angina	www.caladrius.com	2018
Capricor Therapeutics	CAP-1001	Duchenne Muscular Dystrophy	www.capricor.com	2018
Cellerant Therapeutics	Romyelocel-L	Neutropenia Infections	www.cellerant.com	2018
MiMedx	AmnioFix	Osteoarthritis	www.mimedx.com	2018
Nightstar Therapeutics	NSR-REP1	Chorideremia	www.nightstartx.com	2018
Voyager Therapeutics	VY-AADC	Parkinsons	www.voyagertherapeutics.com	2018

Adoptive Cellular Therapy: Immuno-Oncology Landscape



Source – Wells Fargo Securities Conference, November 2017

cryoport SCIENCE. LOGISTICS. CERTAINTY.

Novartis – Kymriah™ Ramp Continues

- Second indication of Kymriah™ for adult r/r DLBCL approved in Q2 2018
- Received positive CHMP opinion for both r/r pediatric & young adult ALL and r/r DLBCL in Q2
- $16 million Q2 2018 commercial revenue for Kymriah™
- Six additional active clinical trials
- Manufactured for over 300 patients in 11 countries and 35 certified treatment centers at end of Q1 2018
- Over 500 employees supporting Kymriah™



Gilead – Yescarta™ Ramp Builds

- Yescarta™ approved in U.S. in October 2017
- Received positive CHMP opinion for r/r DLBCL in Q2 and European approval anticipated in Q3 2018.
- $68 million in net commercial Yescarta™ revenues in Q2 2018
- 61 cancer centers authorized as of June 30, 2018 with access to approximately 80% of eligible patients
- New 117,000 sq ft manufacturing facility leased in the Netherlands to support European distribution
- Entered a new Cooperative Research and Development Agreement with the National Cancer Institute to develop cell therapies targeting patient specific tumor neoantigens

Kite
A GILEAD Company

YESCARTA™
(axicabtagene ciloleucel) Suspension for IV infusion

cryoport
SCIENCE. LOGISTICS. CERTAINTY.

CryoStork℠ for Reproductive Medicine

CryoStork℠

New: *CryoStork℠ Insurance*
Providing Expectant Parents with Peace of Mind

Multi-tiered insurance solution to be offered through Cryoport's network of ~400 fertility clinics

Leveraging the Scalable Business Model

Continuing strong double-digit growth in revenue, year-over-year and sequentially

Net revenue for the six months ended June 30, 2018 vs. prior year ($mm)



Gross margin for the six months ended June 30, 2018 vs. prior year (%)



cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Quarterly Revenue Trends

Continued quarterly revenue growth fueled by revenue expansion from existing clients and new client acquisitions

cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Quarterly Revenue Trends (cont'd)

Biopharma growth continues to be driven by ramp in clinical trials supported and commencement of revenue from the support of commercials therapy launches



Financial Summary

Statements of Operations Data: *(in thousands)*	2015	2016	2017	Q2-2017	Q2-2018	QoQ growth %
Net Revenues	$ 5,525	$ 7,679	$ 11,954	$ 2,917	$ 4,627	58.6%
Biopharma	3,364	5,302	9,113	2,229	3,849	72.6%
Animal Health	869	845	1,135	262	279	6.5%
Reprodcutive Medicine	1,292	1,532	1,707	426	500	17.2%
Cost of revenues	3,847	4,577	5,988	1,524	2,123	
Gross margin (loss)	1,679	3,101	5,966	1,393	2,504	79.7%
Loss from operations	(7,810)	(8,766)	(7,893)	(1,864)	(2,465)	
Adjusted EBITDA	(5,339)	(5,281)	(3,666)	(890)	(821)	
Net loss	$ (16,222)	$ (13,188)	$ (7,899)	$ (1,861)	$ (2,470)	
Net loss per share - basic and diluted	$ (2.72)	$ (0.93)	$ (0.93)	$ (0.08)	$ (0.09)	

Balance sheet data: *(in thousands)*	30-Jun-18
Cash and cash equivalents	$ 20,011
Working capital	21,116
Total assets	27,738
Long term obligations, less current portion	184
Total stockholders' equity	24,422

Added to Russell 2000® Index and Russell 3000® Index



Cryoport added to the Russell 2000 and Russell 3000 Indexes on June 25th

Russell US Indexes widely used by investment managers and institutional investors as the building blocks of a broad range of financial products, such as index tracking funds, derivatives and Exchange Traded Funds (ETFs), as well as being performance benchmarks.

Approximately $9 trillion in assets under management (AUM) are benchmarked to or invested in products based on the Russell US Indexes, 18% of which is to the Russell 2000® alone.

Inclusion in the Indexes increases Cryoport's exposure among investors, provides additional liquidity for the stock and is expected to broaden its shareholder base.

Conclusion


Large & Rapidly Developing Market for Temperature Controlled Logistics for the Life Sciences
Established Brand with Full Cryogenic Logistics Solutions Suite
Strategically Positioned with Leading Clients in the Life Sciences Market
Key Partnerships with Global Transportation Operators
Diversified, Growing, Sticky Client Base
Impressive Revenue Growth
cryoport
SCIENCE. LOGISTICS. CERTAINTY.

Financial Highlights: Q2-2018

Revenue
$4.6M
up 59%

Biopharma revenue
up 73%

34 Phase III trials

Supporting 258 clinical trials

GPS TRACKING

$446,00 revenue from commercial agreements

Reproductive Medicine
up 17%

Gross Margin
54%
up 6.0PP

GLOBAL FACILITY FOOTPRINT

Strong embedded growth with existing clients

1 BEST IN CLASS FLEET PERFORMANCE

Opex up 53% in support of expected growth

$20M Cash
No debt

30 biopharma clients added during the quarter

27.8M share o/s
EPS ($0.09)

All comparisons are on a year-over-year basis

cryoport
SCIENCE. LOGISTICS. CERTAINTY.